Shares in Zealand Pharma surged on Wednesday, with the stock climbing as much as 12% in early Copenhagen trading, as market chatter intensified around the potential of its experimental obesity treatment. The rally pushed the company's market capitalisation past £20bn, reflecting growing confidence in its pipeline amid the booming weight-loss drug sector.
Investors are focusing on Zealand's lead candidate, petrelintide, an amylin analogue being developed for obesity. Unlike popular GLP-1 drugs such as Novo Nordisk's Wegovy, petrelintide targets a different hormonal pathway, which analysts suggest could offer improved tolerability and muscle preservation. The stock move came without a formal company announcement, but traders cited positive whispers from ongoing clinical trials as the catalyst.
The broader obesity drug market has seen explosive growth, with Novo Nordisk and Eli Lilly dominating. However, smaller players like Zealand are attracting attention as the race for next-generation treatments intensifies. 'Zealand's approach could carve out a significant niche if it delivers on safety and efficacy,' said one London-based healthcare analyst. 'For UK investors, this is a reminder of the high-risk, high-reward nature of biotech.'
The surge also lifted European biotech indices, with the Stoxx Europe 600 Health Care index gaining 0.8%. UK pension funds with allocations to global healthcare equities may see indirect benefits, though direct exposure to Zealand remains limited. The FTSE 100 edged 0.3% higher on the day, partly supported by strength in pharmaceutical stocks.
Zealand Pharma has not confirmed any new trial data, and the stock's volatility underscores the speculative nature of early-stage biotech investing. The company is expected to release full phase 2 results for petrelintide later this year, which will be a key catalyst for the shares.